# PRSice Analysis: Fetal Hemoglobin Prediction in Tanzanian Sickle Cell Disease

[![DOI](https://img.shields.io/badge/DOI-pending-orange)]()
[![License](https://img.shields.io/badge/License-MIT-blue.svg)]()
[![PRSice](https://img.shields.io/badge/PRSice-v2.3.5-green)]()
[![Analysis](https://img.shields.io/badge/Analysis-Standard%20PRS-purple)]()

---

## üìä Overview

This repository contains a comprehensive **polygenic risk score (PRS) analysis** with **p-value threshold optimization** for predicting fetal hemoglobin (HbF) levels in Tanzanian sickle cell disease (SCD) patients using **PRSice-2**.

### Study Highlights

- üß¨ **10,000+ p-value thresholds** tested ($5 \times 10^{-8}$ to 0.5)
- üë• **1,527 individuals** from Tanzania (independent validation cohort)
- üìà **2.2 million SNPs** from genome-wide genotyping
- üéØ **Optimal threshold:** $p_T = 0.444$ (968,114 SNPs)
- üìâ **Performance:** R¬≤ = 1.13% (minimal predictive power)
- üåç **African population** - demonstrating PRS challenges in diverse populations
- üìù **Transparent reporting** - important negative result

### Key Finding

Despite rigorous optimization, **genome-wide PRS explains only 1.13% of HbF variance** - demonstrating that **not all complex traits are suitable for PRS-based prediction**. This poor performance reflects HbF's **oligogenic architecture** (dominated by BCL11A) rather than the distributed polygenic effects required for successful PRS.

---

## üìë Table of Contents

- [Background](#background)
- [Study Design](#study-design)
- [Methods](#methods)
- [Key Results](#key-results)
- [Why PRS Performs Poorly](#why-prs-performs-poorly)
- [Clinical Implications](#clinical-implications)
- [Repository Structure](#repository-structure)
- [Requirements](#requirements)
- [Installation](#installation)
- [Usage](#usage)
- [Interpretation](#interpretation)
- [Citation](#citation)
- [Team](#team)
- [License](#license)

---

## Background

### Polygenic Risk Scores (PRS)

**Polygenic risk scores** aggregate genetic effects across many variants to predict trait values or disease risk:

$$\text{PRS}_i = \sum_{j=1}^{M} w_j \cdot G_{ij}$$

where:
- $w_j$ = effect size (weight) for variant $j$ from GWAS
- $G_{ij}$ = genotype (0, 1, 2) for individual $i$ at variant $j$
- $M$ = number of variants included

**Key Challenge:** Which variants to include? Which p-value threshold?

### P-Value Threshold Optimization

PRSice solves this by testing thousands of thresholds:

1. **Strict** ($p_T = 5 \times 10^{-8}$): Only genome-wide significant SNPs
2. **Moderate** ($p_T = 0.01$--$0.1$): Suggestive associations
3. **Relaxed** ($p_T = 0.5$--$1.0$): Include most/all variants

**Optimal threshold** = threshold maximizing prediction accuracy (R¬≤)

### PRS Success Stories

| Trait | Architecture | PRS R¬≤ | Reference |
|-------|--------------|--------|-----------|
| Height | Highly polygenic | 40% | Yengo 2022 |
| Schizophrenia | Polygenic | 7% | Ripke 2014 |
| BMI | Polygenic | 10% | Khera 2019 |
| Type 2 Diabetes | Moderately polygenic | 4% | Mahajan 2018 |

### Why Study HbF?

**Fetal hemoglobin (HbF)** is the most important genetic modifier of SCD severity:
- **Higher HbF** ‚Üí Reduced sickling, fewer complications, better outcomes
- **Heritability** ~ 89% (highly genetic)
- **Known major loci:** BCL11A (chr2), HBS1L-MYB (chr6), HBB cluster (chr11)
- **Clinical relevance:** Predict disease severity, guide treatment

**Question:** Can genome-wide PRS predict individual HbF levels for clinical use?

---

## Study Design

### Input Data

| Component | Description | Details |
|-----------|-------------|---------|
| **GWAS Summary Stats** | Mixed linear model results (GCTA-MLMA) | 8,376,387 SNPs, ŒªGC = 0.987 |
| **Target Genotypes** | Individual-level data (PLINK format) | 1,527 individuals, 2,197,379 SNPs |
| **Phenotype** | Fetal hemoglobin (HbF %) | Continuous quantitative trait (HPLC measured) |
| **Covariates** | Population structure + sex | PC1-PC10 (explain 64% variance!), sex |

### Independent Validation Design

- **Discovery cohort:** 1,683 individuals (GWAS)
- **Validation cohort:** 1,527 individuals (PRS testing)
- **No overlap:** Avoids overfitting, provides honest estimates
- **Trade-off:** Smaller validation sample reduces power

### Analysis Overview

```
GWAS Summary Statistics (2.2M SNPs)
         ‚Üì
Test 10,000+ P-Value Thresholds
         ‚Üì
For Each Threshold:
  - Select SNPs with p < threshold
  - Calculate PRS for each individual
  - Test PRS ~ HbF (adjusting for PCs + sex)
  - Record R¬≤ (variance explained)
         ‚Üì
Identify Optimal Threshold
         ‚Üì
Report Best Performance
```

---

## Methods

### PRSice Workflow

**Step 1: P-Value Threshold Range**
```bash
--lower 5e-08        # Start: genome-wide significance
--upper 0.5          # End: relaxed threshold
--interval 5e-05     # Step size (fine-grained)
```

**Step 2: Variant Selection**

For each threshold $p_T$:
- Include all SNPs with GWAS p-value < $p_T$
- No LD clumping (`--no-clump`)
  - Rationale: African populations have shorter LD blocks
  - Preserves independent signals in close proximity

**Step 3: PRS Calculation**

$$\text{PRS}_i = \sum_{j: p_j < p_T} \beta_j \cdot G_{ij}$$

**Step 4: Association Testing**

$$\text{HbF}_i = \alpha + \beta_{PRS} \cdot \text{PRS}_i + \sum_{k=1}^{10} \gamma_k \cdot \text{PC}_{k,i} + \delta \cdot \text{Sex}_i + \epsilon_i$$

**Step 5: Performance Metrics**

- **Incremental R¬≤:** Variance explained by PRS beyond covariates
- **Full R¬≤:** PRS + covariates
- **Null R¬≤:** Covariates only
- **P-value:** Statistical significance of PRS term

### Command-Line Execution

```bash
./PRSice_linux \
    --base /path/to/gcta_mlma_results.mlma \
    --target data_without_qcfinal \
    --snp SNP --chr Chr --bp bp \
    --a1 A1 --a2 A2 --stat b --pvalue p \
    --beta \
    --binary-target F \
    --cov data_without_qcfinal_qc_covariates.txt \
    --cov-col PC1,PC2,PC3,PC4,PC5,PC6,PC7,PC8,PC9,PC10,Sex \
    --keep data_without_qcfinal.qc.fam \
    --extract data_without_qcfinal.qc.bim \
    --no-clump \
    --lower 5e-08 \
    --upper 0.5 \
    --interval 5e-05 \
    --bar-levels 0.001,0.05,0.1,0.2,0.3,0.4,0.5,1 \
    --num-auto 22 \
    --thread 8 \
    --out debug_MINI
```

**Key Parameters:**
- `--no-clump`: Disable LD clumping (preserve independent signals)
- `--beta`: Effect sizes are regression coefficients
- `--binary-target F`: Continuous phenotype
- `--cov-col`: Include PC1-PC10 and sex as covariates
- `--lower/--upper/--interval`: Define threshold scanning range

---

## Key Results

### Optimal PRS Performance

| Metric | Value | Interpretation |
|--------|-------|----------------|
| **Optimal Threshold** | $p_T = 0.4437$ | Moderate threshold |
| **SNPs Included** | 968,114 | 44% of available SNPs |
| **PRS R¬≤** | **1.13%** | **Minimal prediction** |
| **Full R¬≤ (PRS + Covariates)** | 64.38% | Good overall fit |
| **Null R¬≤ (Covariates only)** | 63.97% | Covariates dominate! |
| **P-value** | $3.3 \times 10^{-5}$ | Statistically significant |
| **Coefficient** | 213.16 | Effect size |

### Performance Across Threshold Spectrum

| Threshold ($p_T$) | SNPs | R¬≤ | P-value | Performance |
|-------------------|------|----|---------|-------------|
| $5 \times 10^{-8}$ (GWS) | 12 | 0.000003% | 0.99 | No signal |
| 0.001 | 2,296 | 0.065% | 0.099 | Weak |
| 0.05 | 13,074 | 0.22% | 0.002 | Weak |
| 0.1 | 39,686 | 0.34% | 0.00004 | Modest |
| 0.3 | 214,827 | 0.40% | 0.000004 | Plateau starts |
| **0.4437 (Optimal)** | **968,114** | **1.13%** | **0.00003** | **Best** |
| 0.5 | 1,082,508 | 0.40% | 0.00004 | Declining |
| 1.0 (All SNPs) | 2,197,379 | 0.39% | 0.00004 | Poor |

### Visualizations

#### PRS Performance Barplot

![PRS Barplot](figures/debug_MINI_BARPLOT_2025-12-08.png)

**Key observations:**
- Optimal threshold ($p_T = 0.444$) shows highest R¬≤ (1.13%)
- Performance much lower at strict thresholds ($p_T < 0.05$)
- Including all variants ($p_T = 1.0$) performs worse than selective inclusion
- Color indicates statistical significance (-log‚ÇÅ‚ÇÄ(p-value))

#### High-Resolution Threshold Scan

![High-Res Plot](figures/debug_MINI_HIGH-RES_PLOT_2025-12-08.png)

**Key observations:**
- Black points: -log‚ÇÅ‚ÇÄ(p-value) at each of 10,000+ thresholds
- Green line: Best-fit curve showing trend
- **Plateau effect:** Performance increases to $p_T \approx 0.3$, then plateaus
- Diminishing returns beyond moderate thresholds
- Optimal threshold ($p_T = 0.44$) near plateau center

---

## Why PRS Performs Poorly

### 1. Oligogenic Architecture

**HbF is NOT polygenic‚Äîit's oligogenic (few major loci):**

| Locus | Gene | Variance Explained | Mechanism |
|-------|------|-------------------|-----------|
| 2p16.1 | BCL11A | 10-15% | Transcriptional repressor |
| 6q23.3 | HBS1L-MYB | 3-8% | Erythroid proliferation |
| 11p15.4 | HBB cluster | 2-5% | Cis-regulatory |
| **Total** | - | **15-28%** | - |

**Implication:** Most genetic variance in 3 loci, minimal polygenic signal.

### 2. Low SNP-Heritability

- **Our GWAS:** $h^2_{SNP} = 4.3\%$
- **Maximum possible PRS R¬≤:** < 4.3%
- **Achieved:** 1.13%
- **Efficiency:** 26% of theoretical maximum

**Why so low?**
- Common variants capture little variance
- Rare variants, structural variants may be important
- Environmental factors substantial (hydroxyurea, malaria)

### 3. Single Dominant Locus Effect

**BCL11A dominates so strongly that:**
- It explains ~10-15% variance alone
- Other genome-wide variants contribute negligibly
- PRS trying to capture "polygenic background" finds minimal signal
- Optimal threshold tries to include more variants but gains little

### 4. The Plateau Effect

**Performance plateaus at $p_T = 0.3$--$0.5$:**
- By $p_T \approx 0.3$, most true associations included
- Beyond this, additional variants are mostly false positives
- Signal exhausted‚Äîthere simply aren't many more causal variants

**Contrast with polygenic traits:**
- Height, schizophrenia: Performance continues improving to $p_T = 1.0$
- Thousands of true associations distributed genome-wide
- HbF: Limited true associations beyond major loci

### 5. Covariates Dominate Prediction

**Striking finding:** Covariates explain 64% variance vs. PRS 1.13%

**Why do PCs explain so much?**

1. **Population Stratification:**
   - Tanzania has diverse ethnic groups (Bantu, Nilotic, Cushitic)
   - PC1 alone explains 17.49% variance (unusually high)
   - Different HbF levels across ethnic groups

2. **PCs as Proxies:**
   - May tag causal variants (e.g., BCL11A has different frequencies)
   - May capture environmental factors (diet, healthcare, malaria)
   - Hard to separate genetic vs. environmental components

---

## Clinical Implications

### Is Genome-Wide PRS Useful for HbF Prediction?

**Answer: NO, not in current form.**

**Reasons:**

1. ‚ùå **Poor Predictive Accuracy:**
   - 1.13% variance explained is clinically negligible
   - Cannot stratify patients into meaningful risk groups
   - Prediction intervals too wide for individual decisions

2. ‚ùå **Covariates More Informative:**
   - PCs + sex explain 64% (57√ó more than PRS)
   - Population ancestry better predictor than genome-wide genetics

3. ‚ùå **Not Cost-Effective:**
   - Genome-wide genotyping: $50-100 per sample
   - Targeted genotyping (3 loci): $5-10 per sample
   - 10√ó cost for 1% improvement‚Äînot justified

### What Should Be Done Instead?

**Recommended Approach:** ‚úÖ **Targeted Genotyping of Major Loci**

```
Step 1: Genotype Known HbF Loci
‚îú‚îÄ‚îÄ BCL11A: rs1427407, rs766432
‚îú‚îÄ‚îÄ HBS1L-MYB: rs9399137, rs4895441
‚îî‚îÄ‚îÄ HBB cluster: rs7482144, XmnI

Step 2: Calculate Locus-Specific Score
HbF_predicted = Œ± + Œ≤‚ÇÅ¬∑BCL11A + Œ≤‚ÇÇ¬∑HBS1L-MYB + Œ≤‚ÇÉ¬∑HBB

Step 3: Clinical Use
‚îú‚îÄ‚îÄ Risk stratification (expected 15-28% R¬≤)
‚îú‚îÄ‚îÄ Treatment planning (hydroxyurea dosing)
‚îú‚îÄ‚îÄ Gene therapy candidacy
‚îî‚îÄ‚îÄ Prognostic counseling
```

**Advantages:**
- ‚úÖ Much better prediction (15-28% vs. 1.13%)
- ‚úÖ Low cost ($5-10 vs. $50-100)
- ‚úÖ Rapid results (same-day PCR)
- ‚úÖ Implementable in resource-limited settings
- ‚úÖ Captures most genetic information

---

## Repository Structure

```
.
‚îú‚îÄ‚îÄ README.md                           # This file
‚îú‚îÄ‚îÄ PRSICE_REPORT_LATEX.tex            # Comprehensive analysis report (LaTeX)
‚îÇ
‚îú‚îÄ‚îÄ data/
‚îÇ   ‚îú‚îÄ‚îÄ gwas/
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ gcta_mlma_results.mlma     # GWAS summary statistics
‚îÇ   ‚îÇ
‚îÇ   ‚îú‚îÄ‚îÄ genotypes/
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ data_without_qcfinal.bed   # PLINK binary genotypes
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ data_without_qcfinal.bim
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ data_without_qcfinal.fam
‚îÇ   ‚îÇ   ‚îú‚îÄ‚îÄ data_without_qcfinal.qc.bim  # QC SNP list
‚îÇ   ‚îÇ   ‚îî‚îÄ‚îÄ data_without_qcfinal.qc.fam  # QC sample list
‚îÇ   ‚îÇ
‚îÇ   ‚îî‚îÄ‚îÄ covariates/
‚îÇ       ‚îî‚îÄ‚îÄ data_without_qcfinal_qc_covariates.txt  # PC1-10, Sex
‚îÇ
‚îú‚îÄ‚îÄ results/
‚îÇ   ‚îú‚îÄ‚îÄ debug_MINI.summary             # Main results file
‚îÇ   ‚îú‚îÄ‚îÄ debug_MINI.prsice              # Full threshold scan results
‚îÇ   ‚îú‚îÄ‚îÄ debug_MINI.best                # Individual PRS at optimal threshold
‚îÇ   ‚îú‚îÄ‚îÄ debug_MINI.log                 # Analysis log
‚îÇ   ‚îÇ
‚îÇ   ‚îî‚îÄ‚îÄ plots/
‚îÇ       ‚îú‚îÄ‚îÄ debug_MINI_BARPLOT_2025-12-08.png
‚îÇ       ‚îî‚îÄ‚îÄ debug_MINI_HIGH-RES_PLOT_2025-12-08.png
‚îÇ
‚îú‚îÄ‚îÄ scripts/
‚îÇ   ‚îú‚îÄ‚îÄ run_prsice.sh                  # Main PRSice analysis script
‚îÇ   ‚îú‚îÄ‚îÄ parse_results.R                # Extract key metrics
‚îÇ   ‚îî‚îÄ‚îÄ visualize_thresholds.R         # Additional plots
‚îÇ
‚îî‚îÄ‚îÄ docs/
    ‚îú‚îÄ‚îÄ METHODS.md                      # Detailed methodology
    ‚îú‚îÄ‚îÄ INTERPRETATION_GUIDE.md         # How to interpret results
    ‚îî‚îÄ‚îÄ COMPARISON_PRSET.md             # Comparison with pathway PRS
```

---

## Requirements

### Software

| Tool | Version | Purpose |
|------|---------|---------|
| **PRSice** | v2.3.5+ | PRS construction and optimization |
| **PLINK** | v1.9+ | Genotype data processing |
| **R** | ‚â• 4.0.0 | Visualization, statistics |

### R Packages

```r
install.packages(c(
  "data.table",   # Fast file I/O
  "ggplot2",      # Plotting
  "dplyr",        # Data manipulation
  "tidyr"         # Data tidying
))
```

### System Requirements

- **CPU:** 4+ cores (8 used in study)
- **RAM:** 16 GB minimum
- **Storage:** ~50 GB for genotype data and intermediate files
- **OS:** Linux (tested on CentOS 7), macOS compatible

---

## Installation

### 1. Clone Repository

```bash
git clone https://github.com/yourusername/tanzania-hbf-prs.git
cd tanzania-hbf-prs
```

### 2. Download PRSice

```bash
# Download PRSice-2
wget https://github.com/choishingwan/PRSice/releases/download/2.3.5/PRSice_linux.zip
unzip PRSice_linux.zip
chmod +x PRSice_linux

# Verify installation
./PRSice_linux --help
```

### 3. Prepare Data Files

```bash
# Ensure your data follows this structure:
# - GWAS summary stats: Chr, SNP, bp, A1, A2, Freq, b, se, p
# - Genotypes: PLINK binary format (.bed/.bim/.fam)
# - Covariates: FID, IID, PC1-PC10, Sex
```

---

## Usage

### Quick Start

```bash
# Run PRS analysis with threshold optimization
bash scripts/run_prsice.sh
```

### Full Command

```bash
./PRSice_linux \
    --base data/gwas/gcta_mlma_results.mlma \
    --target data/genotypes/data_without_qcfinal \
    --snp SNP --chr Chr --bp bp \
    --a1 A1 --a2 A2 --stat b --pvalue p \
    --beta \
    --binary-target F \
    --cov data/covariates/data_without_qcfinal_qc_covariates.txt \
    --cov-col PC1,PC2,PC3,PC4,PC5,PC6,PC7,PC8,PC9,PC10,Sex \
    --keep data/genotypes/data_without_qcfinal.qc.fam \
    --extract data/genotypes/data_without_qcfinal.qc.bim \
    --no-clump \
    --lower 5e-08 \
    --upper 0.5 \
    --interval 5e-05 \
    --bar-levels 0.001,0.05,0.1,0.2,0.3,0.4,0.5,1 \
    --num-auto 22 \
    --thread 8 \
    --out results/my_prs_analysis
```

### Extract Key Results

```r
# Load results
library(data.table)
results <- fread("results/debug_MINI.summary")

# View optimal performance
print(results)
```

---

## Interpretation

### Reading Output Files

#### `.summary` File

Main results file with one row per analysis:

```
Phenotype  Set   Threshold  PRS.R2    Full.R2   Null.R2   Coefficient  P
-          Base  0.4437     0.0113    0.6438    0.6397    213.156      3.3e-05
```

**Key columns:**
- `Threshold`: Optimal p-value threshold
- `PRS.R2`: **Incremental variance explained by PRS**
- `Full.R2`: Total variance (PRS + covariates)
- `Null.R2`: Covariates only
- `P`: Statistical significance

#### `.prsice` File

Detailed results across all tested thresholds (10,000+ rows):

```
Pheno  Set   Threshold  R2      P          Coefficient  Num_SNP
-      Base  5e-08      0.0000  0.991      -0.0005      12
-      Base  0.001      0.0006  0.099      2.58         2,296
...
-      Base  0.4437     0.0113  0.00003    213.16       968,114
...
-      Base  1.0        0.0039  0.00004    427.03       2,197,379
```

**Use for:**
- Plotting performance curves
- Identifying plateau regions
- Sensitivity analysis

#### `.best` File

Individual PRS at optimal threshold:

```
FID    IID      PRS
FAM1   IND1     145.32
FAM2   IND2     -89.17
...
```

**Use for:**
- Individual risk prediction
- Risk stratification
- Clinical decision support

### Understanding Performance Metrics

**R¬≤ Ranges:**
```
R¬≤ > 10%    : Strong prediction ‚úì‚úì‚úì (Clinically useful)
R¬≤ = 5-10%  : Moderate prediction ‚úì‚úì (Some clinical value)
R¬≤ = 1-5%   : Weak prediction ‚úì (Limited utility)
R¬≤ < 1%     : Minimal prediction ‚úó (Not clinically useful)
```

**Our result: R¬≤ = 1.13%** ‚Üí Weak prediction, limited clinical utility

### Statistical vs. Practical Significance

**Important distinction:**

- **Statistically significant** (p = 3.3 √ó 10‚Åª‚Åµ): PRS associated with HbF
- **Practically insignificant** (R¬≤ = 1.13%): Too weak for clinical use

**Lesson:** Small effects can be statistically detectable but clinically irrelevant with large sample sizes.

---

## Comparison: Standard PRS vs. Pathway PRS

We also performed **pathway-based PRS** (PRSet) analysis:

| Approach | Method | Best R¬≤ | Significant? | Conclusion |
|----------|--------|---------|--------------|------------|
| **Standard PRS (PRSice)** | Genome-wide threshold optimization | 1.13% | Yes (p=3e-5) | Weak prediction |
| **Pathway PRS (PRSet)** | Pathway enrichment testing | 9.0%* | No (p=0.005) | No enrichment |

*Top pathway (taurine metabolism) not statistically significant after multiple testing correction.

**Convergent Evidence:**

Both analyses point to **oligogenic architecture**:
- Minimal genome-wide polygenic signal
- No pathway-specific enrichment
- BCL11A dominates genetic variance
- Targeted approach more appropriate than genome-wide

---

## Lessons Learned

### 1. Not All Traits Are Suitable for PRS

**PRS Performance is Trait-Dependent:**

| Trait Type | Architecture | Expected PRS R¬≤ |
|------------|--------------|-----------------|
| Highly polygenic (height) | 1000s variants | 20-40% |
| Polygenic (BMI, T2D) | 100s variants | 5-15% |
| Moderately polygenic (CAD) | 10s variants | 2-8% |
| **Oligogenic (HbF)** | **3-5 major loci** | **<2%** |

**Before investing in PRS:**
1. ‚úÖ Check trait architecture (GWAS Manhattan plot)
2. ‚úÖ Estimate SNP-heritability
3. ‚úÖ Review number of genome-wide significant loci
4. ‚úÖ Consider targeted genotyping if few major loci

### 2. Population Structure Matters

**Challenge in Diverse Populations:**

- Tanzania has substantial within-country genetic diversity
- PC1 alone explains 17.49% variance (very high)
- PCs can be stronger predictor than genome-wide genetics
- Difficult to separate structure from biology

**Recommendations:**
- Use within-ancestry PRS (stratify by ethnicity)
- Model gene √ó environment interactions
- Incorporate local ancestry information
- Be cautious with PC adjustment (may remove signal)

### 3. Negative Results Are Valuable

**This study demonstrates:**

- ‚úÖ Transparent reporting of null findings
- ‚úÖ Poor PRS performance is scientifically informative
- ‚úÖ Clarifies when alternative approaches needed
- ‚úÖ Saves future researchers from repeating failed strategies

**Lesson:** Publish negative results to advance science!

---

## Citation

### Preprint/Paper

> Kabongo EN, Chimusa ER. (2025). Polygenic Risk Score Analysis Reveals Minimal Predictive Utility for Fetal Hemoglobin in Tanzanian Sickle Cell Disease: Implications for Oligogenic Traits. *[Journal]*, [Volume]([Issue]):[Pages]. DOI: [pending]

### BibTeX

```bibtex
@article{kabongo2025prs,
  title={Polygenic Risk Score Analysis Reveals Minimal Predictive 
         Utility for Fetal Hemoglobin in Tanzanian Sickle Cell Disease},
  author={Kabongo, Etienne Ntumba and Chimusa, Emile R},
  journal={[Journal Name]},
  year={2025},
  doi={[pending]}
}
```

### Software Citation

```bibtex
@article{choi2019prsice,
  title={PRSice-2: Polygenic Risk Score software for biobank-scale data},
  author={Choi, Shing Wan and O'Reilly, Paul F},
  journal={GigaScience},
  volume={8},
  number={7},
  year={2019}
}
```

---

## Team

### Principal Investigator

**Prof. Emile R. Chimusa, PhD**  
Department of Computer and Information Sciences  
Northumbria University, Newcastle upon Tyne, UK  
üìß emile.chimusa@northumbria.ac.uk  
üîó [ORCID](https://orcid.org/XXXX-XXXX-XXXX-XXXX)

### Bioinformatics Analyst

**Etienne Ntumba Kabongo, MSc**  
Department of Human Genetics  
McGill University, Montreal, QC, Canada  
üìß etienne.kabongo@mcgill.ca  
üîó [GitHub](https://github.com/yourusername)  
üîó [LinkedIn](https://linkedin.com/in/yourprofile)

---

## Acknowledgments

- **Study participants and families** for their generous contribution
- **Centre for High Performance Computing (CHPC), South Africa** for computational resources
- **PRSice-2 developers** Shing Wan Choi and Paul F. O'Reilly
- **Tanzania National Institute for Medical Research (NIMR)**
- **Funding agencies:** [To be added]

---

## Contributing

We welcome contributions to improve analysis pipelines and documentation:

1. Fork the repository
2. Create feature branch (`git checkout -b feature/improvement`)
3. Commit changes (`git commit -am 'Add new feature'`)
4. Push to branch (`git push origin feature/improvement`)
5. Submit Pull Request

---

## License

This project is licensed under the **MIT License** - see the [LICENSE](LICENSE) file for details.

---

## Related Resources

### Publications

- [Main GWAS paper] - Genome-wide association study of HbF in Tanzania
- [PRSice-2 paper] - Choi & O'Reilly, GigaScience 2019
- [Pathway analysis] - Companion PRSet pathway enrichment study

### Tools

- **PRSice-2:** https://choishingwan.github.io/PRSice/
- **PLINK:** https://www.cog-genomics.org/plink/
- **GCTA:** https://yanglab.westlake.edu.cn/software/gcta/

### Tutorials

- **PRSice Tutorial:** https://choishingwan.github.io/PRSice/step_by_step/
- **PRS Guidelines:** https://www.nature.com/articles/s41596-020-0353-1

---

## Support

For questions or collaboration requests:

**Prof. Emile Chimusa**  
üìß emile.chimusa@northumbria.ac.uk

**Etienne Ntumba Kabongo**  
üìß etienne.kabongo@mcgill.ca

---

## Keywords

`Polygenic Risk Score` `PRSice` `P-Value Threshold Optimization` `Fetal Hemoglobin` `Sickle Cell Disease` `BCL11A` `Tanzania` `African Genomics` `Oligogenic Trait` `Prediction Accuracy` `GWAS` `Precision Medicine` `Negative Results`

---

<p align="center">
  <img src="https://img.shields.io/badge/Science-Transparent-blue?style=for-the-badge" />
  <img src="https://img.shields.io/badge/Results-Reproducible-green?style=for-the-badge" />
  <img src="https://img.shields.io/badge/Null-Results%20Matter-orange?style=for-the-badge" />
</p>

<p align="center">
  <i>"Not all complex traits are polygenic. Poor PRS performance is scientifically informative."</i>
</p>

---

**Version:** 1.0  
**Last Updated:** December 10, 2025  
**Status:** Analysis Complete  
**Manuscript Status:** In Preparation
